Clinical Trials

Clinical Trial Number: NSABP B55

Treatment trial for patients diagnosed with germline BRCA 1/2 mutations and high-risk HER2 negative breast cancer

Eligibility Criteria

  • Must be 18 years or older
  • Must have triple negative breast cancer defined as one of the following:
    • ER and PgR negative and HER2 negative (not eligible for anti-HER2 therapy)
    • ER and/or PgR positive, HER2 negative
  • Must have documented germline mutation in the genes BRCA1 or BRCA2 that is known or predicted to be detrimental (leading to loss of function)
  • Must have completed breast and axilla surgery, and at least six cycles of adjuvant or neoadjuvant chemotherapy

Additional criteria may apply.